Expertise in
1
conditions

Jingxun H. Wu

Xiamen, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Xiamen, CN 

Overview

Jingxun Wu practices practicing medicine in Xiamen, China.

Wu is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), NUT Carcinoma, and Laryngeal Cancer.

They are actively involved in clinical research, co-authoring 54 peer reviewed articles and participating in 2 clinical trials.

Locations

Xiamen, 361003, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Tislelizumab+Cisplatin or Carboplatin+Pemetrexed, Cisplatin or Carboplatin+Pemetrexed
Study Phase: Phase 3
View 1 Less Clinical Trial

54 Total Publications

Expert consensus on the detection and clinical application of tumor mutational burden.
Expert consensus on the detection and clinical application of tumor mutational burden.
Journal: Cancer biology & medicine
Published: February 18, 2026

Frequently Asked Questions about Jingxun H. Wu

Is Jingxun H. Wu a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Jingxun H. Wu is classified as an Advanced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jingxun H. Wu participate in research or clinical trials?

Yes. Jingxun H. Wu has published 54 articles and abstracts on conditions like Lung Cancer. You can view a list of Jingxun H. Wu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wu's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile